GOSS Stock Recent News

GOSS LATEST HEADLINES

GOSS Stock News Image - PennyStocks

Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?

PennyStocks 2022 Dec 13
GOSS Stock News Image - Seeking Alpha

Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept.

Seeking Alpha 2022 Dec 08
GOSS Stock News Image - Proactive Investors

Gossamer Bio Inc stock lost three quarters of its value today as the market questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial despite an upbeat assessment from the company. “We are very pleased to share that seralutinib significantly improved hemodynamic, biomarker, and right heart structural and functional measures in a heavily treated pulmonary arterial hypertension patient population,” said Faheem Hasnain, CEO of Gossamer.

Proactive Investors 2022 Dec 06
GOSS Stock News Image - InvestorPlace

Gossamer Bio (NASDAQ: GOSS ) is one of the top-trending tickers on social media today, and its shares are plunging more than 70%. The company announced that a trial of its drug for hypertension, seralutinib, had met the primary goal in a Phase 2 trial.

InvestorPlace 2022 Dec 06
GOSS Stock News Image - Market Watch

Shares of Gossamer Bio Inc. GOSS, +2.99% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s MRK, -0.03% sotatercept.

Market Watch 2022 Dec 06
GOSS Stock News Image - Zacks Investment Research

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research 2022 Nov 08
GOSS Stock News Image - Invezz

Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside.

Invezz 2022 Oct 20
GOSS Stock News Image - Zacks Investment Research

Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research 2022 Jul 19
GOSS Stock News Image - PennyStocks

Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks 2022 Jul 16
9 of 29